ORG-12962 is a pyridinylpiperazine

drug A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed. Drugs are typically distinguished from food and substances that provide nutritional support. Consumption of drugs can be via insuffla ...

developed by Organon, which acts as a potent and selective

agonist An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...

for the 5-HT₂

receptor Receptor may refer to: * Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse *Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...

family, with highest

affinity Affinity may refer to: Commerce, finance and law * Affinity (law), kinship by marriage * Affinity analysis, a market research and business management technique * Affinity Credit Union, a Saskatchewan-based credit union * Affinity Equity Partn ...

at 5-HT_2C and lowest at 5-HT_2B subtypes. It was developed as a potential anti-anxiety drug, but was discontinued from human trials after tests in a public speaking challenge showed that its anti-anxiety effects were accompanied by side effects such as dizziness and a "spacey" feeling, which were attributed to poor selectivity ''in vivo'' over the hallucinogenic 5-HT_2A

Synthesis

Note that patent serves to deliver 1- -chloro-5-(trifluoromethyl)pyridin-2-yliperazine 32834-59-4 although patent is correct one
CID:9796408
Hence, ORG-12962, would need 2,6-Dichloro-3-(trifluoromethyl)pyridine 5304-75-1 ORG-12962 synthesis

2,3-dichloro-5-trifluoromethylpyridine 9045-84-7

References

Serotonin receptor agonists Piperazines Trifluoromethyl compounds Aminopyridines {{nervous-system-drug-stub

Synthesis

See also

References